Seladin-1 is a novel lipopolysaccharide (LPS)-responsive gene and inhibits the tumour necrosis factor-alpha production and osteoclast formation in response to LPS.
Selective Alzheimer disease indicator-1 (seladin-1) is a broadly expressed oxidoreductase and is related to Alzheimer disease, cholesterol metabolism and carcinogenesis. The effect of lipopolysaccharide (LPS) on the expression of seladin-1 was examined using RAW 264.7 macrophage-like cells and murine peritoneal macrophages. Lipopolysaccharide induced the expression of seladin-1 protein and messenger RNA in those macrophages. The seladin-1 expression was also augmented by a series of Toll-like receptor ligands. The LPS augmented the expression of seladin-1 via reactive oxygen species generation and p38 activation. Seladin-1 inhibited LPS-induced activation of p38 but not nuclear factor-kappaB and inhibited the production of tumour necrosis factor-alpha in response to LPS. Moreover, seladin-1 inhibited LPS-induced osteoclast formation and enhanced LPS-induced alkaline phosphatase activity. Therefore, it was suggested that seladin-1 might be an LPS-responsible gene product and regulate the LPS-induced inflammatory response negatively.
Khuda
Imtiaz I-E
II
Department of Microbiology and Immunology, Aichi Medical University School of Medicine, Nagakute, Aichi, Japan.
Koide
Naoki
N
Noman
Abu S M
AS
Dagvadorj
Jargalsaikhan
J
Tumurkhuu
Gantsetseg
G
Naiki
Yoshikazu
Y
Komatsu
Takayuki
T
Yoshida
Tomoaki
T
Yokochi
Takashi
T
D000818:Animals; D002460:Cell Line; D008070:Lipopolysaccharides / Q000276:immunology / Q000494:pharmacology*; D008264:Macrophages / Q000187:drug effects* / Q000276:immunology; D017737:Macrophages, Peritoneal / Q000187:drug effects / Q000276:immunology / Q000378:metabolism; D051379:Mice; D009419:Nerve Tissue Proteins / Q000187:drug effects / Q000235:genetics / Q000378:metabolism*; D010010:Osteoclasts / Q000166:cytology / Q000378:metabolism; D044925:Oxidoreductases Acting on CH-CH Group Donors / Q000187:drug effects / Q000235:genetics / Q000378:metabolism*; D016133:Polymerase Chain Reaction; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors* / Q000096:biosynthesis / Q000187:drug effects
D008070:Lipopolysaccharides; D009419:Nerve Tissue Proteins; D014409:Tumor Necrosis Factor-alpha; D044925:Oxidoreductases Acting on CH-CH Group Donors
Nature. 2007 Jun 21;447(7147):972-8
17538624
Cell. 2000 Dec 22;103(7):1071-83
11163183
J Neurosci. 2000 Oct 1;20(19):7345-52
11007892
Nat Rev Immunol. 2006 Nov;6(11):823-35
17063184
J Clin Lab Immunol. 1984 Nov;15(3):155-61
6530697
Am J Hum Genet. 2001 Oct;69(4):685-94
11519011
J Biol Chem. 2009 Dec 25;284(52):36442-36452
19861417
Nat Immunol. 2005 Jun;6(6):587-92
15864310
J Mol Endocrinol. 2008 Nov;41(5):251-61
18768664
Science. 2000 Sep 29;289(5488):2350-4
11009421
J Endocrinol Invest. 2005 Mar;28(3):285-93
15954227
Nat Cell Biol. 1999 Jun;1(2):94-7
10559880
Curr Opin Immunol. 2005 Aug;17(4):338-44
15950447
Trends Mol Med. 2007 Nov;13(11):460-9
18029230
Genes Dev. 1995 Jan 1;9(1):97-107
7828854
Periodontol 2000. 2007;43:65-84
17214836
Am J Med Genet. 1998 Jan 13;75(2):145-52
9450875
Proc Natl Acad Sci U S A. 1999 Feb 16;96(4):1761-6
9990098
Endocrinology. 2008 Jul;149(7):3267-73
18339707
Nature. 2004 Dec 2;432(7017):640-5
15577914
Lancet. 1996 Aug 10;348(9024):404
8709748
Proc Natl Acad Sci U S A. 1998 Nov 24;95(24):14395-9
9826711
Mol Cell Biol. 2008 Jan;28(2):539-50
17984220
Clin Exp Immunol. 2009 Mar;155(3):552-8
19220841
Biochem Biophys Res Commun. 2007 Aug 24;360(2):346-51
17597583
J Clin Invest. 1997 Sep 15;100(6):1557-65
9294124
Nat Rev Immunol. 2005 Jun;5(6):446-58
15928677